Cargando…
COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
BACKGROUND: Multiple myeloma (MM) and Waldenström macroglobulinemia (WM) are associated with significant immunoparesis. Based on the ongoing COVID-19 pandemic, there is an urgent need to understand whether patients are able to mount a sufficient response to COVID-19 vaccines. METHODS: MM and WM pati...
Autores principales: | Branagan, Andrew R., Lei, Matthew M, Maron, Jenny S, Yee, Andrew J, O'Donnell, Elizabeth, Castillo, Jorge J., Raje, Noopur S., Treon, Steven P, Flynn, Catherine A, Mo, Clifton C., Nadeem, Omar, Richardson, Paul G., Panaroni, Cristina, Meid, Kirsten, Bernstein, Zachary S., Lyons, Rebecca T., Hunter, Zachary R, Guerrera, Maria Luisa, Gammon, Marilyn T., Lively, Kathleen J., Packer, Lisette, Waterman, Matthew, Gallagher, Raquel, Juleg, Boris, Alter, Galit, Sarosiek, Shayna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701550/ http://dx.doi.org/10.1182/blood-2021-154089 |
Ejemplares similares
-
Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021) -
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew, et al.
Publicado: (2021) -
Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
por: Jenner, Matthew W, et al.
Publicado: (2021) -
CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021) -
Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2021)